DHA effect on chemotherapy-induced body weight loss: An exploratory study in a rodent model of mammary tumors

Nutrition and Cancer

Volumn 64, Issue 7, 2012, Pages 1000-1007

  Hajjaji, Nawale ^a,b   Couet, Charles ^a,b,c   Besson, Pierre ^a,c   Bougnoux, Philippe ^a,b,c  

^a CHRU de Tours   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; DOXORUBICIN; ICOSAPENTAENOIC ACID; PLACEBO;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BREAST TUMOR; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CONTROLLED STUDY; DIET; FEMALE; FOOD INTAKE; KIDNEY DISEASE; NONHUMAN; RAT; TUMOR GROWTH; WEIGHT GAIN; WEIGHT REDUCTION;

ADIPOSE TISSUE; ANIMALS; CACHEXIA; DIET; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; DOXORUBICIN; EATING; EICOSAPENTAENOIC ACID; FEMALE; GLYCEROL; MAMMARY NEOPLASMS, EXPERIMENTAL; RATS; RATS, SPRAGUE-DAWLEY; WEIGHT LOSS;

EID: 84867818317     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2012.714832     Document Type: Article

References (42)

1. DeWys, W D, Begg, C, Lavin, P T, Band, P R, Bennett, J M. 1980. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med, 69: 491-497.
2. Moses, A WG, Slater, C, Preston, T, Barber, M D, and, Fearon, K CH. 2004. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer, 90: 996-1002.
3. Fearon, K C H, Voss, A C, and, Hustead, D S. 2006. on behalf of the Cancer Cachexia Study Group: Definition of cancer cachexia: effect of weight loss, reduced food intake and systemic inflammation on functional status and prognosis. Am J Clin Nutr, 83: 1345-1350.
4. Bachmann, J, Heiligensetzer, M, Krakowski-Roosen, H, Bchler, M W, Friess, H. 2008. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg, 12: 1193-1201.
5. Mitchell, E P. 2006. Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol, 33: 106-120.
6. Murphy, R A, Mourtzakis, M, Chu, Q S, Baracos, V E, Reiman, T. 2011. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer, 117: 1775-1782.
7. Antoun, S, Birdsell, L, Sawyer, M B, Venner, P, Escudier, B. 2010. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol, 28: 1054-1160.
8. Tisdale, M J. 2002. Cachexia in cancer patients. Nat Rev Cancer, 2: 862-871.
9. Barber, M D, Ross, J A, Voss, A C, Tisdale, M J, and, Fearon, K C. 1999. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer, 81: 80-86.
10. Barber, M D, Preston, T, McMillan, D C, Slater, C, Ross, J A. 2004. Modulation of the liver export protein synthetic response to feeding by an n-3 fatty-acid-enriched nutritional supplement is associated with anabolism in cachectic cancer patients. Clin Sci (Lond), 106: 359-364.
11. Wigmore, S J, Barber, M D, Ross, J A, Tisdale, M J, and, Fearon, K C. 2000. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer, 36: 177-184.
12. Burns, C P, Halabi, S, Clamon, G, Kaplan, E, Hohl, R J. 2004. Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. Cancer, 101: 370-378.
13. van der Meij, B S, Langius, J A, Smit, E F, Spreeuwenberg, M D, von Blomberg, B M. 2010. Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment. J Nutr, 140: 1774-1780.
14. Bougnoux, P, Hajjaji, N, Ferrasson, M N, Giraudeau, B, Couet, C. 2009. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer, 101: 1978-1985.
15. Colas, S, Mahéo, K, Denis, F, Goupille, C, Hoinard, C. 2006. Sensitization by dietary docosahexaenoic acid of rat mammary carcinoma to anthracycline: a role for tumor vascularization. Clin Cancer Res, 12: 5879-5886.
16. Minotti, G, Licata, S, Saponiero, A, Menna, P, Calafiore, A M. 2000. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and (4Fe-4S) reactivity of its secondary alcohol metabolite. Chem Res Toxicol, 13: 1336-1341.
17. Mitra, M S, Donthamsetty, S, White, B, Latendresse, J R, and, Mehendale, H M. 2007. Mechanism of protection of moderately diet restricted rats against doxorubicin-induced acute cardiotoxicity. Toxicol Appl Pharmacol, 225: 90-101.
18. Taniyama, Y, and, Walsh, K. 2002. Elevated myocardial Akt signaling ameliorates doxorubicin-induced congestive heart failure and promotes heart growth. J Mol Cell Cardiol, 34: 1241-1247.
19. Giri, S N, Al-Bayati, M A, Du, X, Schelegle, E, Mohr, F C. 2004. Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats. Cancer Chemother Pharmacol, 53: 141-150.
20. Lui, R C, Laregina, M C, Herbold, D R, and, Johnson, F E. 1986. Testicular cytotoxicity of intravenous doxorubicin in rats. J Urol, 136: 940-943.
21. Freireich, E J, Gehan, E A, Rall, D P, Schmidt, L H, and, Skipper, H E. 1966. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep, 50: 219-244.
22. Hajjaji, N, Schubnel, V, and, Bougnoux, P. 2011. Determinants of DHA incorporation into tumor tissue during dietary DHA supplementation. Lipids, 46: 1063-1069.
23. Folch, J, Lees, M, and, Sloane Stanley, G H. 1957. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem, 226: 497-509.
24. Childs, C E, Romeu-Nadal, M, Burdge, G C, and, Calder, P C. 2010. The polyunsaturated fatty acid composition of hepatic and plasma lipids differ by both sex and dietary fat intake in rats. J Nutr, 140: 245-250.
25. Tisdale, M J, and, Beck, S A. 1991. Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochem Pharmacol, 41: 103-107.
26. Nurjhan, N, Kennedy, F, Consoli, A, Martin, C, Miles, J. 1988. Quantification of the glycolytic origin of plasma glycerol: implications for the use of the rate of appearance of plasma glycerol as an index of lipolysis in vivo. Metabolism, 37: 386-389.
27. Lhuillery, C, Bougnoux, P, Groscolas, R, and, Durand, G. 1995. Time-course study of adipose tissue fatty acids during mammary tumor growth in rats with controlled fat intake. Nutr Cancer, 24: 299-309.
28. Alemán, C L, Más, R M, Rodeiro, I, Noa, M, Hernández, C. 1998. Reference database of the main physiological parameters in Sprague-Dawley rats from 6 to 32 months. Lab Anim, 32: 457-466.
29. Mettler, F P, Young, D M, and, Ward, J M. 1977. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res, 37: 2705-2713.
30. Hardman, W E, Avula, C P, Fernandes, G, and, Cameron, I L. 2001. Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer xenografts. Clin Cancer Res, 7: 2041-2049.
31. Shao, Y, Pardini, L, and, Pardini, R S. 1997. Intervention of transplantable human mammary carcinoma MX-1 chemotherapy with dietary menhaden oil in athymic mice: Increased therapeutic effects and decreased toxicity of cyclophosphamide. Nutr Cancer, 28: 63-73.
32. Xue, H, Sawyer, M B, Field, C J, Dieleman, L A, and, Baracos, V E. 2007. Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor. Clin Cancer Res, 13: 7146-7154.
33. Xue, H, Le Roy, S, Sawyer, M B, Field, C J, Dieleman, L A. 2009. Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-(4-(1-piperidino)-1- piperidino)carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colon tumour. Br J Nutr, 102: 434-442.
34. Horie, T, Nakamaru, M, and, Masubuchi, Y. 1998. Docosahexaenoic acid exhibits a potent protection of small intestine from methotrexate-induced damage in mice. Life Sci, 62: 1333-1338.
35. Atkinson, T G, Barker, H J, and, Meckling-Gill, K A. 1997. Incorporation of long-chain n-3 fatty acids in tissues and enhanced bone marrow cellularity with docosahexaenoic acid feeding in post-weanling Fischer 344 rats. Lipids, 32: 293-302.
36. Atkinson, T G, Murray, L, Berry, D M, Ruthig, D J, and, Meckling-Gill, K A. 1997. DHA feeding provides host protection and prevents fibrosarcoma induced hyperlipidemia while maintaining the tumor response to araC in Fischer 344 rats. Nutr Cancer, 28: 225-235.
37. Gronn, M, Christensen, E, Hagve, T A, and, Christophersen, B O. 1991. Peroxisomal retroconversion of docosahexaenoic acid (22:6(n-3)) to eicosapentaenoic acid (20:5(n-3)) studied in isolated rat liver cells. Biochim Biophys Acta, 1081: 85-91.
38. Hardman, W E, Moyer, M P, and, Cameron, I L. 1999. Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects. Br J Cancer, 81: 440-448.
39. Gauthier, M S, Favier, R, and, Lavoie, J M. 2006. Time course of the development of non-alcoholic hepatic steatosis in response to high-fat diet-induced obesity in rats. Br J Nutr, 95: 273-281.
40. Tisdale, M J. 1996. Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia. Nutrition, 12: S31-S33.
41. Gava, M H, Couto, R C, Oyama, L M, Couto, G E, Silveira, V L. 2001. Polyunsaturated fatty acid-rich diets: effect on adipose tissue metabolism in rats. Br J Nutr, 86: 371-377.
42. Rustan, A C, Hustvedt, B E, and, Drevon, C A. 1993. Dietary supplementation of very long-chain n-3 fatty acids decreases whole body lipid utilization in the rat. J Lipid Res, 34: 1299-1309.